BME : ROVI.MC

Laboratorios Farmaceuticos Rovi, S.A.

$57.2 EUR

$1 (1.78%)

Volume
138.34K
Average Volume
153.66K
Market Capitalization
$2.93B
P/E Ratio
22.26
Dividend Yield
1.68%
Price Target
Year High
$86.70
Year Low
$51.65
Day High
—
Day Low
—
Payout Ratio
$0.36
Current Ratio
$3.66
Company Overview

BME

Juan Lopez-Belmonte Encina

Drug Manufacturers - Specialty & Generic

Healthcare

ROVI.MC

2232

ES

EUR

https://www.rovi.es

34 91 021 30 00

N/A

N/A

Liquidity Metrics

0.17

3.66

1.80

0.66

0.36

Sales & Valuation

$743.48M

3.95

4.34

25.48

2.24

Profitability

$2.75

$140.44M

17.79%

23.30%

20.89%

14.23%

P/E Metrics

22.26

-0.62

-0.62

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Financial Health Scores

9.81

4/9

$391.75M

$926.32M

$239.58M

$168.75M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Rosario Perucha Pérez Marketing Director
Francisco Javier Angulo García Human Resources Manager
Javier Lopez-Belmonte Encina First Deputy Chairman, GM of Industrial Operations & Chief Financial Officer
Mercedes Benítez del Castillo Sánchez Chief Legal Officer
Miguel Ángel Ortega Sánchez Chief Industrial Officer
Ivan Jorge Lopez-Belmonte Encina Second Deputy Chairman and Chief Commercial & Development Officer
Juan Lopez-Belmonte Encina Chairman & Chief Executive Officer
Alicia Hurtado Morales Chief Compliance Officer
María Álvarez Solas Chief Operating Officer
Marta Campos Martínez Head of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI.MC) Stock

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Bree ... zhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.

Frequently Asked Questions

What is the current Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) stock price?

Laboratorios Farmaceuticos Rovi, S.A.(BME:ROVI.MC) stock price is $57.2 in the last trading session. During the trading session, ROVI.MC stock reached the peak price of $86.7 while $51.65 was the lowest point it dropped to. The percentage change in ROVI.MC stock occurred in the recent session was 1.78% while the dollar amount for the price change in ROVI.MC stock was $1.

ROVI.MC's industry and sector of operation?

The BME listed ROVI.MC is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of ROVI.MC?

Rosario Perucha Pérez | Marketing Director
Francisco Javier Angulo García | Human Resources Manager
Javier Lopez-Belmonte Encina | First Deputy Chairman, GM of Industrial Operations & Chief Financial Officer
Mercedes Benítez del Castillo Sánchez | Chief Legal Officer
Miguel Ángel Ortega Sánchez | Chief Industrial Officer

How many employees does ROVI.MC have?

Number of ROVI.MC employees currently stands at 2232. ROVI.MC operates from Calle José Isbert, 2, Madrid, None 28223, ES.

Link for ROVI.MC official website?

Official Website of ROVI.MC is: https://www.rovi.es

How do I contact ROVI.MC?

ROVI.MC could be contacted at phone #34 91 021 30 00 and can also be accessed through its website. ROVI.MC operates from Calle José Isbert, 2, Madrid, None 28223, ES.

How many shares of ROVI.MC are traded daily?

The average number of ROVI.MC shares traded daily for last 3 months was 153.66K.

What is the market cap of ROVI.MC currently?

The market value of ROVI.MC currently stands at $2.93B with its latest stock price at $57.2